India Pharma Outlook Team | Tuesday, 24 February 2026
Akums Drugs & Pharmaceuticals Ltd. has secured EU GMP certification for two of its manufacturing facilities in India, strengthening its position in regulated European markets.
The approval includes the renewal of certification for its oral solid dosage facility, which manufactures tablets, capsules, and sachets, along with fresh certification for its oral liquid facility producing solutions, syrups, and suspensions. With this EU GMP certification, the company reinforces its compliance with globally recognized quality standards.
The development expands Akums’ ability to serve customers across the European Union while maintaining strict regulatory and manufacturing benchmarks. The certification confirms that both facilities meet the quality and safety requirements expected in highly regulated markets.
Also Read: The Future of MedTech in India: Meeting Tier-2 and Tier-3 Needs
The company has also marked its entry into the United Kingdom with its first UK MHRA approval for Rivaroxaban. This approval represents Akums’ direct entry into the UK anticoagulant market and signals its broader global ambitions.
Commenting on the milestone, Sandeep Jain, Managing Director, said: “We built scale, compliance and credibility in India. Our vision now extends with the same commitment to Europe and the UK. What we have achieved domestically, we are determined to replicate globally—with quality, reliability and long-term partnerships.”
Akums currently serves more than 1,500 clients worldwide. It operates 14 manufacturing plants, including 12 formulation facilities and two API plants, with a combined annual production capacity exceeding 50 billion units.
